Louisiana Attorney General Liz Murrill and Alliance Defending Freedom have urged the FDA to restore the in-person dispensing requirement for the abortion drug mifepristone, criticizing the agency for delaying its safety study update until March. They argue that the FDA's 2023 decision to remove this requirement has been deemed unlawful by multiple courts and that the delay puts nearly 1,000 unborn babies in Louisiana at risk each month from mail-order abortion drugs.
Read →Loading search…